Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma

RAO Wenchen; SONG Xiaobing

doi:10.6039/j.issn.1001-0408.2023.01.15

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma

更新时间：2023-02-22

- Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma
- ZHONGGUO YAOFANG Vol. 34, Issue 1, Pages: 78-81(2023)
- 作者机构：
  
  1.联勤保障部队第九〇〇医院仓山院区呼吸科，福州　350004
  2.赣州市第五人民医院质控科，江西赣州　341099
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.01.15
  CLC： R956
- Published：15 January 2023，
  
  Received：13 June 2022，
  
  Revised：18 December 2022，
扫描看全文
饶文晨,宋晓兵.布地奈德2种吸入给药方案用于轻度哮喘的药物经济学评价 ^Δ[J].中国药房,2023,34(01):78-81.

RAO Wenchen,SONG Xiaobing.Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma[J].ZHONGGUO YAOFANG,2023,34(01):78-81.
饶文晨,宋晓兵.布地奈德2种吸入给药方案用于轻度哮喘的药物经济学评价 ^Δ[J].中国药房,2023,34(01):78-81. DOI： 10.6039/j.issn.1001-0408.2023.01.15.

RAO Wenchen,SONG Xiaobing.Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma[J].ZHONGGUO YAOFANG,2023,34(01):78-81. DOI： 10.6039/j.issn.1001-0408.2023.01.15.

摘要

目的

从我国卫生体系角度出发，评价轻度哮喘患者按需吸入布地奈德/福莫特罗与布地奈德维持治疗联合按需吸入特布他林（以下简称“布地奈德维持治疗”）的经济性。

方法

基于一项国际多中心随机对照临床研究（SYGMA 2研究）建立轻度哮喘Markov模型，模拟时限为60年，循环周期为1周。成本仅纳入直接医疗成本，效用值来自SYGMA 2研究中五水平欧洲五维健康量表数据和文献数据。测算轻度哮喘患者上述2种吸入治疗方案的总成本和总产出，贴现率为5%，并采用敏感性分析评价基础研究结果的稳健性。

结果

按需吸入布地奈德/福莫特罗方案与布地奈德维持治疗方案的总成本分别为25 884、45 822元，效用值分别为30.51、30.50 质量调整生命年，前者为绝对优势方案。单因素敏感性分析结果显示，药品（特布他林、布地奈德/福莫特罗）的价格和平均每天吸入次数是主要影响参数，但对基础分析结果影响不大。概率敏感性分析结果显示，按需吸入布地奈德/福莫特罗方案具有经济性的概率为100%。

结论

与布地奈德维持治疗方案相比，轻度哮喘患者使用按需吸入布地奈德/福莫特罗方案更具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-utility of as-needed inhaled budesonide/formoterol versus budesonide maintenance therapy combined with as-needed inhaled terbutaline （hereinafter referred to as budesonide maintenance therapy） in patients with mild asthma from the perspective of the Chinese health service system.

METHODS

A Markov model of mild asthma was established based on an international multicenter randomized controlled clinical study （SYGMA 2 study）； the model cycle was one week， and the model had a whole horizon of 60 years. The cost only included direct medical cost， and utility value was derived from the data of EuroQol 5-Dimension 5-Level in the SYGMA 2 study and published literature. The total cost and total output of the above two inhalation therapies for patients with mild asthma were calculated， with discount rate of 5%. The stability of the model was evaluated by sensitivity analysis.

RESULTS

The total cost of as-needed inhaled budesonide/formoterol and budesonide maintenance therapy were 25 884 yuan and 45 822 yuan， respectively， and the effectiveness were 30.51 quality-adjusted life years （QALYs） and 30.50 QALYs， respectively. The former scheme was an absolute advantage. One-way sensitivity analyses showed that the price of drug （terbutaline and budesonide/formoterol） and average number of inhalations per day were the main influencing parameters， but they had little influence on the results of basic analysis. Probabilistic sensitivity analysis showed that the probability of as-needed budesonide/formoterol being cost-effective was 100%.

CONCLUSIONS

Compared with budesonide maintenance therapy， as-needed inhalation of budesonide/formoterol in mild asthma patients is more cost-effective.

关键词

轻度哮喘布地奈德福莫特罗特布他林药物经济学评价按需用药维持治疗

Keywords

budesonideformoterolterbutalinepharmacoeconomic evaluationas-neededmaintenance therapy

references

中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南：2020年版[J].中华结核和呼吸杂志，2020，43（12）：1023-1048.

LIN J T，WANG W Y， CHEN P， et al. Prevalence and risk factors of asthma in mainland China：the CARE study[J]. Respir Med，2018，137：48-54.

HUANG K W，YANG T，XU J Y，et al. Prevalence，risk factors，and management of asthma in China：a national cross-sectional study[J]. Lancet，2019，394（10196）：407-418.

BATEMAN E D，REDDEL H K，O’BYRNE P M，et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma[J]. N Engl J Med，2018，378（20）：1877-1887.

O’BYRNE P M，FITZGERALD J M，Bateman E D，et al. Inhaled combined budesonide-formoterol as needed in mild asthma[J].N Engl J Med，2018，378（20）：1865-1876.

FITZGERALD J M，ARNETORP S，SMARE C，et al. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK[J]. Respir Med，2020，171：106079.

REDDEL H K，TAYLOR D R，BATEMAN E D，et al. An official American Thoracic Society/European Respiratory Society statement：asthma control and exacerbations：standardizing endpoints for clinical asthma trials and clinical practice[J]. Am J Respir Crit Care Med，2009，180（1）：59-99.

国务院人口普查办公室，国家统计局人口和就业统计司.中国2010年人口普查资料[EB/OL].[2022-04-06].http：//www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htmhttp://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm.

WATSON L，TURK F，JAMES P，et al. Factors associated with mortality after an asthma admission：a national United Kingdom database analysis[J]. Respir Med，2007，101（8）：1659-1664.

ROBERTS N J，LEWSEY J D，GILLIES M，et al. Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland：a retrospective cohort study from 1981 to 2009[J]. Respir Med，2013，107（8）：1172-1177.

孙利华. 药物经济学[M]. 4版. 北京：中国医药科技出版社，2019：121-127.

谢华，陈萍，张志远，等. 施行规范化管理10年单中心住院支气管哮喘患者调查结果分析[J]. 中华结核和呼吸杂志，2019，42（3）：179-184.

LLOYD A，PRICE D，BROWN R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK[J]. Prim Care Respir J，2007，16（1）：22-27.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：27-28，44-45.

SADATSAFAVI M，FITZGERALD J M，O’BYRNE P M，et al. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada[J]. Allergy Asthma Clin Immunol，2021，17（1）：108.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

美沙酮维持治疗门诊药品规范化管理探讨

Related Author

胡进平俞红丁以星夏福林徐建荣陈玉林柯金兰

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰